Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
No effective treatment exists for patients with X-linked myotubular myopathy (XLMTM), a fatal congenital muscle disease caused by deficiency of the lipid phosphatase, myotubularin. The Mtm1δ4 and Mtm1 p.R69C mice model severely and moderately symptomatic XLMTM, respectively, due to differences in the degree of myotubularin deficiency. Contractile function of intact extensor digitorum longus (EDL) and soleus muscles from Mtm1δ4 mice, which produce no myotubularin, is markedly impaired. Contractile forces generated by chemically skinned single fiber preparations from Mtm1δ4 muscle were largely preserved, indicating that weakness was largely due to impaired excitation contraction coupling. Mtm1 p.R69C mice, which produce small amounts of myotubularin, showed impaired contractile function only in EDL muscles. Short-term replacement of myotubularin with a prototypical targeted protein replacement agent (3E10Fv-MTM1) in Mtm1δ4 mice improved contractile function and muscle pathology. These promising findings suggest that even low levels of myotubularin protein replacement can improve the muscle weakness and reverse the pathology that characterizes XLMTM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NetCGlyc 1.0: Prediction of mammalian C-mannosylation sites
Julenius, K. (2007) · Glycobiology · doi:10.1093/glycob/cwm050 · Cited by 174
Cited by
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
Congenital myopathies: disorders of excitation–contraction coupling and muscle contraction
Jungbluth, H., Treves, S., Zorzato, F., Sarkozy, A., Ochala, J., Sewry, C., Phadke, R., Gautel, M., & Muntoni, F. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.191 · Cited by 280
Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007523 · Cited by 173
Self-citationSystemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs
Mack, D. L., Poulard, K., Goddard, M. A., Latournerie, V., Snyder, J. M., Grange, R. W., Elverman, M. R., Denard, J., Veron, P., Buscara, L., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.004 · Cited by 114
“No disease-modifying therapies are currently available for patients, but initial AAV-mediated gene transfer experiments in animal models demonstrated dramatic phenotype improvement and suggested that effective treatment might be possible for XLMTM.(7,8)”
BackgroundMethodInfluentialSelf-citationX-linked myotubular myopathy: A prospective international natural history study
Annoussamy, M., Lilien, C., Gidaro, T., Gargaun, E., Chê, V., Schara, U., Gangfuß, A., D'Amico, A., Dowling, J. J., Darras, B. T., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007319 · Cited by 94
Self-citationBeggs, A. H., Byrne, B. J., De Chastonay, S., Haselkorn, T., Hughes, I., James, E. S., Kuntz, N. L., Simon, J., Swanson, L. C., Yang, M. L., et al. (2018) · Muscle & Nerve · doi:10.1002/mus.26018 · Cited by 83
“Procedure not specified 2 (6) 3 (5) 5 (5) Nervous system disorders 7 (19) 12 (19) 19 (19) Hypotonia 6 (17) 5 (8) 11 (11) Injury, poisoning and procedural complications 1 (3) 16 (26) 17 (17) Investigations 1 (3) 13 (21) 14 (14) Cardiac disorders 3 (8) 7 (11) 10 (10) Hepatobiliary disorders 0 6 (10) 6 (6) Metabolism and…”
InfluentialSelf-citationLong-term effects of systemic gene therapy in a canine model of myotubular myopathy
Elverman, M., Goddard, M. A., Mack, D., Snyder, J. M., Lawlor, M. W., Meng, H., Beggs, A. H., Buj‐Bello, A., Poulard, K., Marsh, A. P., et al. (2017) · Muscle & Nerve · doi:10.1002/mus.25658 · Cited by 65
Self-citation
Metadata
- Authors
- Lawlor, M. W., Armstrong, D., Viola, M. G., Widrick, J. J., Meng, H., Grange, R. W., Childers, M. K., Hsu, C. P., O'Callaghan, M., Pierson, C. R., Buj-Bello, A., & Beggs, A. H.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-09
- Volume
- 22
- Issue
- 8
- Pages
- 1525-1538
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2161830105
- Cited by
- 87
- References
- 1
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.